

YAKUGAKU ZASSHI Instructions for Authors

The Journal will accept original and innovative submissions in English or Japanese from both members and non-members of the Pharmaceutical Society of Japan, on the understanding that the work is unpublished and is not being considered for publication elsewhere. All authors must agree with the contents of the paper and give their consent for submission of the paper.

Only manuscripts that are written in clear and concise English will be accepted for review. For non-native English-speaking authors, please note that only manuscripts that have already been checked and edited by a native English-speaking person with sufficient scientific knowledge will be accepted. English editing and revision will be conducted on manuscripts whose English grammar, spelling, *etc.* is judged to be inadequate by the Editorial Board of the Pharmaceutical Society of Japan. The editing fee will be charged to the authors.

I. TYPES OF MANUSCRIPT

The Journal publishes Reviews (Comprehensive and Short), Regular Articles, Notes, Communications, and Articles. The journal also publishes invited Reviews. Manuscripts in English or Japanese.

1. Reviews:

(1) **Comprehensive · Short:** Describing the research results of the author. The work need not be complete, however, supporting experimental data must be described.

(2) **Invited Reviews:** Reviews are submitted by invitation from the editorial board, and encompass recent important scientific discoveries.

2. **Regular Articles:** New, significant, innovative, and original findings are suitable as Regular Articles.

3. **Notes:** Papers containing new facts and important data derived from incomplete or partial studies may be suitable as a Note.

4. **Articles:** Surveys and experimental research including new, important findings.

5. **Communications:** Communications should contain new, important information which has not been published and for which urgent publication is desirable. An explanatory statement is required for urgent publication. In general, a Communication should not exceed 2 printed pages. Please indicate in the cover letter the reason why the manuscript should be treated as a Communication.

II. REVIEWS

1. With the exception of Invited Reviews, manuscripts will be reviewed by two or more referees, whose opinions will form the basis of the final decision by the editor.

2. Please submit the revised manuscript no later than two months from the date of notification of manuscript revision by the editor, by logging onto "Author Login" in Online Submission. A manuscript that is not revised within two months may be rejected.

III. SUBMISSION GUIDELINES

The manuscript should be submitted as a PDF file using the "Online Submission" section in our website (<http://yakushi.pharm.or.jp>). Up to 3 files can be submitted; a cover letter, the manuscript, and a supplemental data.

IV. MANUSCRIPT PREPARATION

1. **Cover letter** The cover letter should be in one PDF file. It should include information on the corresponding author (the corresponding author's name, affiliation and address, telephone/fax numbers, and e-mail address), and for non-native English speaking authors, the name of the native English speaker or company that checked the manuscript for correct English usage. For contributions from Japan, the corresponding author's name and address should be written in Japanese as well as English.

As for communications, please indicate in the cover letter the reason why the manuscript should be treated as a Communication.

Please insert supporting documents such as a copy of the approval letter from the ethics committee, certificate of editing by a qualified native English speaker, *etc.* after page 1.

2. **Manuscript** A manuscript, including all figures and tables, should be in one PDF file. Please use Times New Roman or MS Mincho font with a font size of 12pt. All chemical compound numbers and other numbers should be Arabic numbers. Paper size should be A4 (210 mm × 297 mm). Tables can be displayed horizontally if necessary.

(1) **Title page** The title page (page 1) should start with the journal name (YAKUGAKU ZASSHI) and the type of manuscript (Review (Comprehensive, Short), Regular Article, Note, *etc.*). This should be followed by the appropriate section for the manuscript (*i.e.* one of the following: Physical Chemistry, Inorganic Chemistry, Organic Chemistry, Medicinal Chemistry, Pharmacognosy, Analytical Chemistry, Biology/Biochemistry, Biopharmacy, Pharmacology, Hygienic Chemistry, Clinical Pharmacy, Pharmacy Education, Pharmaco-informatics, Annals of Pharmacy, Social Pharmacy), the title, name(s) of the author(s) and affiliation(s), and mailing address in English (and Japanese for Japanese authors). For English-language manuscripts, only the name should be in Japanese and English (Japanese nationals only). An asterisk (*) should be added to the right of the corresponding author's name. Please indicate the corresponding author's e-mail address in the footnote.

(2) **Summary and Keywords** Page 2 should contain a summary no longer than 250 words as well as 3 to 6 descriptive keywords, listed in decreasing order of importance. The first 3 keywords must be independent, as they will be used in a keyword combination in the index (within 80 characters).

(3) **Main Text** The text, acknowledgments, and references should be presented in this order. The figures, tables, or chart/diagram, list of figure legends should appear in English.

Please insert the figures and tables in the appropriate locations within the body of the manuscript. After a manuscript has been accepted, you will be requested to formally submit your paper in electronic format.

V. MANUSCRIPT FORM

1. Affiliations When there are two or more authors and they belong to more than one affiliation, the connection between each author and his or her affiliation should be indicated by italicized superscripts *a*, *b*, *c*, ... placed after each author's name and before each affiliation.

Examples for describing affiliations and mailing addresses:

^a*Department of Molecular Biology, Graduate School of Pharmaceutical Sciences, Hokkaido University*, ^b*Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060-0812, Japan*, ^c*Institute for Genetic Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-0815, Japan*, and ^d*Graduate School of Agriculture, Hokkaido University, Kita 9, Nishi 9, Kita-ku, Sapporo 060-8589, Japan*.

2. Abbreviations Abbreviations must be spelled out in full at their initial appearance, followed by the abbreviation in parentheses. Thereafter, the abbreviation only may be used. Please limit to an absolute minimum the use of abbreviations in the title.

However, the following need not be defined: ADP (adenosine 5'-diphosphate), AIDS (acquired immunodeficiency syndrome), AMP (adenosine 5'-monophosphate or adenylic acid), ATP (adenosine 5'-triphosphate), cAMP (adenosine 3',5'-cyclic monophosphate), cDNA (complementary DNA), CoA (coenzyme A), DNA (deoxyribonucleic acid), ED₅₀ (50% effective dose), ESR (electron spin resonance), FAB-MS (fast atom bombardment mass spectrometry), FAD (flavin adenine dinucleotide), GC-MS (gas chromatography-mass spectrometry), GLC (gas-liquid chromatography), GMP (guanosine 5'-monophosphate), HPLC (high-performance liquid chromatography, high-pressure liquid chromatography), IC₅₀ (inhibitory concentration, 50%), IR (infrared), LC (liquid chromatography), LC/MS (liquid chromatography/mass spectrometry), LD₅₀ (50% lethal dose), mRNA (messenger RNA), MS (mass spectrum), NMR (nuclear magnetic resonance), P450 (as in cytochrome P450), RNA (ribonucleic acid), TLC (thin-layer chromatography), tRNA (transfer RNA), UV (ultraviolet)

3. Units The following units should be used: length (m, cm, mm, μ m, nm, Å), mass (kg, g, mg, μ g, ng, pg, mol, mmol), volume (l, ml, μ l), time (s, min, h, d), temperature (°C, K), radiation (Bq, Ci, dpm, Gy, rad), and concentration (M, mM, mol/l, mmol/l, mg/ml, μ g/ml, %, % (v/v), % (w/v), ppm, ppb)

4. Spectral and Elemental Analysis Data Please report spectral and elemental analysis data in the following format. ¹H-NMR (CDCl₃) δ : 1.25 (3H, d, *J* = 7.0 Hz), 3.55 (1H, q, *J* = 7.0 Hz), 6.70 (1H, m). ¹³C-NMR (CDCl₃) δ : 20.9 (q), 71.5 (d), 169.9. IR (KBr) cm⁻¹: 1720, 1050, 910. UV λ_{max} (EtOH) nm (ϵ): 241 (10860), 288 (9380). UV λ_{max} (H₂O) nm (log ϵ): 280 (3.25). FAB-MS *m/z*: 332.1258 (Calcd for C₁₈H₂₀O₆: 332.1259). MS *m/z*: 332 (M⁺), 180, 168. [α]_D²³ -74.5 (*c* 1.0, MeOH). *Anal.* Calcd for C₁₉H₂₁NO₃: C, 73.29; H, 6.80; N, 4.50. Found: C, 73.30; H, 6.88; N, 4.65.

5. Nomenclature The nomenclature used for chemical compounds shall be in accordance with the nomenclature rules formulated by IUPAC. Alternatively, naming may conform to the nomenclature in the index of *Chemical Abstracts* or the Ring Index.

6. References and Notes "References" include articles published in journals, books, on the Internet, and others (technical reports, patents, lectures, *etc.*). References other than those indicated above should be described in the text. References should be numbered consecutively according to their order of appearance in the text (one Arabic number should be assigned to one reference). An Arabic number followed by a parenthesis should be placed after the last relevant word and all references should be listed in numerical order at the end of the text in the section entitled References and Notes. Abbreviations for Journals should conform to Chemical Abstracts (*cf.* The ACS Style Guide. A Manual for Authors and Editors).

Examples of references are as follows:

- 1) Okuyama E., Gao L.-H., Yamazaki M., *Yakugaku Zasshi*, **110**, 834–838 (1990).
- 2) Yamazaki M., Maebayashi Y., Iwase N., *Chem. Pharm. Bull.*, **36**, 2075–2078 (1988).
- 3) Keilhauer G., Faissner A., Schachner M., *Nature* (London), **316**, 728–730 (1985).
- 4) Kawai S., Tanaka S., "Encyclopedia of Experimental Chemistry, Vol. 17, Reaction of organic compounds I," ed. by The Chemical Society of Japan, Maruzen Co., Ltd., Tokyo, 1963, pp. 1–243.
- 5) Cruickshank R., Duguid I. P., Marmion B. P., Swain R. H. A., "Medical Microbiology," 12nd ed., Vol. III, Churchill Livingstone, New York, 1975.
- 6) Szejtli J., "Cyclodextrin Technology," ed. by Davis J. E. D., Kluwer Academic, Dordrecht, 1988.
- 7) Tokuda H., Ichiishi E., Onozuka M., Yamaguchi S., "Biology of Nitric Oxide, Part 6," Vol. I Chap. 2, eds. by Moncada S., Tada N., Maeda H., Portland Press, London, 1998, pp. 185–186.
- 8) Brunner A., Greune H., U.S. Patent 1910462 (1933) [*Chem. Abstr.*, **27**, 4092–4096 (1993)]
- 9) Mochizuki M., Inami K., Abstracts of papers, the 119th Annual Meeting of the Pharmaceutical Society of Japan, Tokushima, March 1999, No. 2, p. 79.
- 10) International Organization for Standardization. "How ISO develops standards.": <http://www.iso.org/iso/about/how_iso_develops_standards.htm>, cited 25 August, 2008

In the list of references in the References section, include the last names and initials of the first and middle names for all authors.

For references appearing in the main text, the last names of the first 2 authors only should be written. For references with 3 or more authors, write the name of the first author followed by *et al.* (Example: Jones A. B., *et al.*).

VI. X-RAY CRYSTAL STRUCTURE ANALYSES

When structure determination by X-ray crystallographic analysis is a central theme of a paper, the data required for registration with the Cambridge Crystallographic Data Centre (CCDC) should be attached as supplementary material. Although this does not apply in cases where crystallographic analysis plays only a supplementary role, crystal data (unit cell parameters, space group, Z density) and R-factor should still be noted. Atomic coordinates will be printed when the structure is important. Bond lengths and angles, thermal parameters, and torsion angles will be printed when they are important for the issues addressed in the paper. When papers have been accepted, the authors are advised to register the data with CCDC.

VII. NUCLEOTIDE SEQUENCES

Newly reported nucleotide sequences must be deposited in one of the data banks, (either DDBJ, GenBank, or EMBL) and an accession number must be obtained before the paper will be accepted by the Editorial Board. Access to the information in the database must be available at the time of publication. A footnote will be included in the paper indicating that such a deposit has been made.

VIII. ETHICS

1. For manuscripts dealing with scientific investigations involving human subjects and/or human tissues, the experiments should be performed in accordance with the ethical standards formulated in the Helsinki Declaration of 1964 (<http://www.wma.net/en/30publications/10policies/b3/>) and/or the ethical standards for clinical research (<http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/index.html#4>), while experiments dealing with the human genome should be conducted according to the Japanese government's "Ethical Standards for Human Genome and Genetic Analysis Research" (http://www.lifescience.mext.go.jp/bioethics/hito_genome.html). Furthermore, only studies that have been performed after receiving approval from the appropriate ethics committee of an institution will be accepted for publication. Finally, please clearly state in the manuscript that the study was performed according to these guidelines and attach to the cover letter a scanned certificate from the ethics committee.

2. Manuscripts describing animal experiments should be conducted in accordance with the experimental animal guidelines of the institution as well as the appropriate government guidelines, such as those published by the Japanese Ministry of Education, Culture, Sports, Science and Technology. Only manuscripts of experiments conducted in accordance with the appropriate guidelines will be eligible for publication. Finally, please state clearly within the manuscript which guidelines were followed and that the study was indeed conducted in accordance with the guidelines.

IX. CHARGES

1. Submission Fee: The one-time fee of 3000 Japanese yen/manuscript, payable by credit card, will be applied to new submissions only.
2. Page Charge: 4000 Japanese yen per printed page.
3. Reprint Charges (Japanese yen)

Number of Pages Number of Reprints	Number of Pages					
	1~2	3~4	5~6	7~8	9~10	Greater than 11
50	¥8000	¥9000	¥10000	¥11000	¥12000	¥13000
100	¥14400	¥16200	¥18000	¥19800	¥21600	¥23400
150	¥19200	¥21600	¥24000	¥26400	¥28800	¥31200
200	¥22400	¥25200	¥28000	¥30800	¥33600	¥36400
More than 250	¥110 each	¥120 each	¥130 each	¥150 each	¥160 each	¥180 each

- Postage included; Tax extra.
- Reprints only available in multiples of 50.
- Color printing carries an extra surcharge of ¥80 per page.
- Cover charge: ¥30 each (upon request only).

4. Actual cost for color figures: ¥50000 per page.

5. Actual cost for English revision and editing.

The charges do not include consumption tax.

The Journal reserves the right to modify the charges without prior notification.

The page charge should be paid, but is not a condition for publication, since the decision for publication is made on the basis of scientific significance only. The publication charge may be waived upon request from authors who do not have sufficient funds. No free reprints of the article will be provided in such cases.

X. OTHER IMPORTANT POINTS

1. In general, after a paper has been reviewed, no authors may be added or deleted from the paper, and the order of the names of the authors cannot be changed.
2. The authors are given an opportunity to proofread the galley of an accepted manuscript. No additions and revisions are allowed other than the correction of typographical errors.
3. The copyrights of all manuscripts published in the *Yakugaku Zasshi* belong to the Pharmaceutical Society of Japan. The author must submit a Copyright Transfer form to the Pharmaceutical Society of Japan.

Yakugaku Zasshi Editorial Office, The Pharmaceutical Society of Japan
2-12-15, Shibuya, Shibuya-ku, Tokyo 150-0002, Japan